The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00070583" target="_blank" >RIV/00216224:14110/13:00070583 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/13:33143920 RIV/65269705:_____/13:#0002106

Výsledek na webu

<a href="http://dx.doi.org/10.1038/leu.2013.171" target="_blank" >http://dx.doi.org/10.1038/leu.2013.171</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2013.171" target="_blank" >10.1038/leu.2013.171</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

Popis výsledku v původním jazyce

The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph_) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that weredeveloped in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies.

Název v anglickém jazyce

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

Popis výsledku anglicky

The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph_) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that weredeveloped in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

2016-2022

Kód UT WoS článku

000325642600008

EID výsledku v databázi Scopus

—